Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Epigenetic drivers of disease progression in multiple myeloma

Felipe Prósper • 28 Sep 2023
IMS 2023
Multiple Myeloma Rare Diseases Smoldering Myeloma

In this video, Felipe Prósper, MD, PhD, University of Navarra, Pamplona, Spain, discusses the role of epigenetics in the pathogenesis of multiple myeloma, highlighting novel transcription factors that have been identified and may play a role in disease progression, including IRF-2. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Felipe Prósper

1:44
The impact of CAR density on the antitumoral efficacy of BCMA CAR-T cells in multiple myeloma
Felipe Prósper • 28 Sep 2023
1:00
The role of the immune microenvironment in disease progression in multiple myeloma
Felipe Prósper • 28 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals